Chimeric Therapeutics Ltd (ASX:CHM) non-executive director Cindy Elkins has demonstrated her confidence in the company’s bio-tech strategy with the purchase of shares in an on-market transaction.
Elkins acquired 24,800 shares in an indirect interest on March 8 at A$0.3178 per share, marking her first purchase in the company.
Board appointment
Chimeric recently appointed Dr Eliot Bourk as its vice president, Business and Corporate Development to drive the growth of its cancer therapy pipeline by advancing strategic business opportunities, initiatives and partnerships.
Dr Bourk will lead business and corporate development, with a near-term focus on Chimeric Therapeutics additional novel cell therapies.
He joined Chimeric from Kite Pharmaceuticals, where he led early commercial strategy, responsible for the optimisation of a portfolio of early-stage cell therapy pipeline assets and for guiding business development strategies and transactions.